Condition: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) · Sponsor: Arvinas Inc.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
This description comes directly from the study's public registry record.
Arvinas Operations, Inc. · 475-345-0791 · clinicaltrialsARV-393@arvinas.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | New Haven, Connecticut, United States | Recruiting |
| Clinical Trial Site | Detroit, Michigan, United States | Recruiting |
| Clinical Trial Site | New Brunswick, New Jersey, United States | Recruiting |
| Clinical Trial Site | New York, New York, United States | Recruiting |
| Clinical Trial Site | New York, New York, United States | Recruiting |
| Clinical Trial Site | Cleveland, Ohio, United States | Recruiting |
| Clinical Trial Site | Nashville, Tennessee, United States | Recruiting |
| Clinical Trial Site | Houston, Texas, United States | Recruiting |
| Clinical Trial Site | Toronto, Ontario, Canada | Recruiting |
| Clinical Trial Site | Montreal, Quebec, Canada | Recruiting |
| Clinical Trial Site | Copenhagen, Denmark | Recruiting |
| Clinical Trial Site | Odense C, Denmark | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06393738